These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 1388119)
1. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Palmer GC; Murray RJ; Wilson TC; Eisman MS; Ray RK; Griffith RC; Napier JJ; Fedorchuk M; Stagnitto ML; Garske GE Epilepsy Res; 1992 Jun; 12(1):9-20. PubMed ID: 1388119 [TBL] [Abstract][Full Text] [Related]
2. Classification of compounds for prevention of NMDLA-induced seizures/mortality, or maximal electroshock and pentylenetetrazol seizures in mice and antagonism of MK801 binding in vitro. Palmer GC; Harris EW; Ray R; Stagnitto ML; Schmiesing RJ Arch Int Pharmacodyn Ther; 1992; 317():16-34. PubMed ID: 1456842 [TBL] [Abstract][Full Text] [Related]
3. Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Garske GE; Palmer GC; Napier JJ; Griffith RC; Freedman LR; Harris EW; Ray R; McCreedy SA; Blosser JC; Woodhead JH Epilepsy Res; 1991 Sep; 9(3):161-74. PubMed ID: 1660399 [TBL] [Abstract][Full Text] [Related]
4. Anticonvulsant properties of calcium channel blockers in mice: N-methyl-D-,L-aspartate- and Bay K 8644-induced convulsions are potently blocked by the dihydropyridines. Palmer GC; Stagnitto ML; Ray RK; Knowles MA; Harvey R; Garske GE Epilepsia; 1993; 34(2):372-80. PubMed ID: 7681002 [TBL] [Abstract][Full Text] [Related]
5. Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. Subramaniam S; Donevan SD; Rogawski MA J Pharmacol Exp Ther; 1996 Jan; 276(1):161-8. PubMed ID: 8558426 [TBL] [Abstract][Full Text] [Related]
6. Preclinical profile of stereoisomers of the anticonvulsant remacemide in mice. Palmer GC; Stagnitto ML; Ordy JM; Griffith RC; Napier JJ; Gentile RJ; Woodhead JH; White HS; Swinyard EA Epilepsy Res; 1991; 8(1):36-48. PubMed ID: 2060502 [TBL] [Abstract][Full Text] [Related]
7. Remacemide HCl and its metabolite, FPL 12495AA, limit action potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture. Wamil AW; Cheung H; Harris EW; McLean MJ Epilepsy Res; 1996 Feb; 23(1):1-14. PubMed ID: 8925800 [TBL] [Abstract][Full Text] [Related]
8. Remacemide hydrochloride: a novel antiepileptic agent. Davies JA Gen Pharmacol; 1997 Apr; 28(4):499-502. PubMed ID: 9147015 [TBL] [Abstract][Full Text] [Related]
11. The effect of the desglycinyl metabolite of remacemide on cortical wedges prepared from DBA/2 mice. Hu RQ; Davies JA Eur J Pharmacol; 1995 Dec; 287(3):251-6. PubMed ID: 8991798 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia. Palmer GC; Cregan EC; Borrelli AR; Harris EW; Stagnitto ML; Colombo P; Kaiser FC; Murray RJ; Griffith RC; Strand JC J Pharmacol Exp Ther; 1995 Aug; 274(2):991-1000. PubMed ID: 7636764 [TBL] [Abstract][Full Text] [Related]
13. Effects of anticonvulsants in a novel operant learning paradigm in rats: comparison of remacemide hydrochloride and FPL 15896AR to other anticonvulsant agents. Hudzik TJ; Palmer GC Epilepsy Res; 1995 Jul; 21(3):183-93. PubMed ID: 8536672 [TBL] [Abstract][Full Text] [Related]
14. The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) on endogenous amino acid release from mouse cortex. Srinivasan J; Richens A; Davies JA Br J Pharmacol; 1995 Dec; 116(8):3087-92. PubMed ID: 8719781 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the anticonvulsant properties of F-721. Swinyard EA; Wolf HH; White HS; Skeen GA; Stark LG; Albertson T; Pong SF; Drust EG Epilepsy Res; 1993 May; 15(1):35-45. PubMed ID: 8391982 [TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Villetti G; Bregola G; Bassani F; Bergamaschi M; Rondelli I; Pietra C; Simonato M Neuropharmacology; 2001 Jun; 40(7):866-78. PubMed ID: 11378157 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022 [TBL] [Abstract][Full Text] [Related]
19. Effects of remacemide and its metabolite FPL 12495 on spike-wave discharges, electroencephalogram and behaviour in rats with absence epilepsy. van Luijtelaar EL; Coenen AM Neuropharmacology; 1995 Apr; 34(4):419-25. PubMed ID: 7566473 [TBL] [Abstract][Full Text] [Related]
20. The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex. Tricklebank MD; Bristow LJ; Hutson PH; Leeson PD; Rowley M; Saywell K; Singh L; Tattersall FD; Thorn L; Williams BJ Br J Pharmacol; 1994 Nov; 113(3):729-36. PubMed ID: 7858861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]